Lly Stock slides after HSBC downgrade despite GLP-1 boom
NEW YORK — 11: 45 a. m. ET Tuesday — lly stock dropped about 5. 9% Tuesday as HSBC downgraded the shares and lowered its price target, even while Eli Lilly’s GLP-1 franchise continues to drive a major share of company revenue. The downgrade sharpened investor focus on looming price pressure, intensifying competition in obesity drugs, and questions about whether long-term GLP-1 revenue expectations are too optimistic. The move lands as the market watches regulatory timing and commercial execution risks around Lilly’s oral GLP-1 candidate, orforglipron, with an FDA decision expected in April.
What moved the market in Lly Stock on Tuesday
The immediate catalyst for the selloff was HSBC’s downgrade and reduced price target, which flagged a cluster of risks around the durability of Lilly’s weight-loss growth story. At issue: potential pricing pressure, rising competition in the obesity drug market, and the possibility that long-term revenue expectations for GLP-1 medicines have been set too high.
Even as demand for GLP-1 therapies has surged worldwide, investor attention is shifting to how access and affordability could reshape the market. Both Lilly and its primary weight-loss rival Novo Nordisk have already introduced multiple price cuts in response to pressure from the U. S. government during 2025 and 2026 to improve patient access to GLP-1 medicines. That sets up an environment where higher volumes must increasingly offset lower pricing, injecting uncertainty into aggressive long-term expectations for obesity-drug revenue.
Competitive pressure: Novo Nordisk’s pill option and Lilly’s regulatory clock
Lilly’s blockbuster tirzepatide injections, Mounjaro for type II diabetes and Zepbound for obesity, have delivered exceptional sales growth in just over three years on the market. Together, the two medicines now account for more than half of Lilly’s total revenues, reinforcing how central GLP-1 therapies are to the company’s growth narrative.
But the competitive landscape is moving quickly. Novo Nordisk’s semaglutide injections—Ozempic for type II diabetes and Wegovy for obesity—compete directly with Mounjaro and Zepbound. Novo Nordisk also strengthened its positioning in late December when the FDA approved an oral version of Wegovy, which was commercially launched in early January. The approval made Wegovy the first GLP-1 therapy available as a pill for weight management, introducing a needle-free option that could broaden adoption.
Lilly is pursuing its own oral path. The company has filed regulatory applications in the United States, Europe, and other markets seeking approval for its oral GLP-1 candidate, orforglipron, for obesity. A potential FDA decision is expected in April, but investor caution has been elevated by the fact that the FDA delayed its decision once earlier in 2026, contributing to recent volatility. Even if approved, Lilly still faces execution questions, including whether patient adherence to an oral therapy meets expectations and whether pricing dynamics limit commercial upside.
Compounded tirzepatide overhang and safety warning enters the debate
Another pressure point for sentiment is the continued availability of compounded versions of tirzepatide in certain channels, despite an FDA crackdown. That ongoing presence could temper demand for Lilly’s branded therapies, adding a separate layer of uncertainty to near-term expectations.
Last week, Lilly raised safety concerns about certain compounded versions of tirzepatide. The company warned that some compounded formulations are being mixed with vitamin B12, which can create an unidentified impurity through a chemical reaction between the two substances. Lilly said the safety profile of this impurity is unknown, and potential effects on toxicity, immune reactions, drug activity, and metabolism have not been studied.
For investors, the compounded-drug issue intersects with the broader pricing and access debate: as affordability becomes more central to patient uptake, pricing dynamics—not product differentiation alone—may play a larger role in market share outcomes.
Quick context
Lilly remains a dominant player in the global obesity market, with recent growth heavily driven by GLP-1 demand. Tuesday’s slide reflects a reassessment of what competition, price cuts, compounded availability, and regulatory timing could mean for future growth.
What’s next
Market attention now turns to two near-term pressure points: how pricing cuts and competition reshape demand, and whether the April FDA decision on orforglipron removes a key uncertainty or extends volatility. Until clarity emerges, traders are likely to keep reacting quickly to new signals on access, competition, and compounded-drug channels that could swing expectations for lly stock.
